We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.88%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.2B
AUM Growth
+$12M
Cap. Flow
-$165M
Cap. Flow %
-3.93%
Top 10 Hldgs %
34.34%
Holding
127
New
6
Increased
36
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$21.9M
2
BSX icon
Boston Scientific
BSX
+$14M
3
MRUS
Merus
MRUS
+$10.5M
4
AGL icon
Agilon Health
AGL
+$8.99M
5
BPMC
Blueprint Medicines
BPMC
+$8.35M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$111M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$40.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$25.9M
4
PEN icon
Penumbra
PEN
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$19.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Staples 1.04%
3 Industrials 0.9%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LFST icon
51
Lifestance Health
LFST
$4.63B
$26.5M 0.63%
2,900,000
– –
RYTM icon
52
Rhythm Pharmaceuticals
RYTM
$8B
$26.3M 0.63%
1,597,123
– –
TVTX icon
53
Travere Therapeutics
TVTX
$5.82B
$23.5M 0.56%
1,527,720
+251,070
+20% +$4.57M
DVAX
54
DELISTED
Dynavax Technologies
DVAX
$23.4M 0.56%
1,813,758
– –
BMRN icon
55
BioMarin Pharmaceuticals
BMRN
$12.4B
$22.9M 0.55%
264,500
– –
AZTA icon
56
Azenta
AZTA
$1.51B
$21.9M 0.52%
469,900
+38,700
+9% +$1.69M
MLYS icon
57
Mineralys Therapeutics
MLYS
$2.41B
$19.9M 0.47%
1,167,492
– –
INZY
58
DELISTED
Inozyme Pharma
INZY
$19.1M 0.45%
3,428,084
+213,184
+7% +$1.26M
RVMD icon
59
Revolution Medicines
RVMD
$43.9B
$18.8M 0.45%
702,712
– –
BMEA icon
60
Biomea Fusion
BMEA
$90.6M
$18.4M 0.44%
836,898
-460,315
-35% -$14.4M
BCRX icon
61
BioCryst Pharmaceuticals
BCRX
$2.45B
$17.6M 0.42%
2,497,193
+163,108
+7% +$1.31M
CMPX icon
62
Compass Therapeutics
CMPX
$393M
$17.5M 0.42%
5,513,788
– –
IRON icon
63
Disc Medicine
IRON
$2.98B
$16.1M 0.38%
363,468
+50,000
+16% +$1.77M
WRBY icon
64
Warby Parker
WRBY
$3.22B
$15.5M 0.37%
1,325,000
+25,000
+2% +$285K
KDNY
65
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$15.2M 0.36%
396,280
-111,232
-22% -$2.86M
CYTK icon
66
Cytokinetics
CYTK
$10.3B
$14.6M 0.35%
447,600
– –
BSX icon
67
Boston Scientific
BSX
$72.5B
$14.5M 0.34%
+267,500
New +$14M
CLDX icon
68
Celldex Therapeutics
CLDX
$3.29B
$14.3M 0.34%
421,615
+111
+0% +$3.74K
COLL icon
69
Collegium Pharmaceutical
COLL
$915M
$14M 0.33%
650,000
– –
FOLD
70
DELISTED
Amicus Therapeutics
FOLD
$13.4M 0.32%
1,063,806
– –
MRUS
71
DELISTED
Merus
MRUS
$12.6M 0.3%
+478,531
New +$10.5M
AURA icon
72
Aura Biosciences
AURA
$812M
$12.6M 0.3%
1,019,757
– –
HCAT icon
73
Health Catalyst
HCAT
$131M
$11.6M 0.28%
929,900
– –
MRSN
74
DELISTED
Mersana Therapeutics
MRSN
$11.2M 0.27%
136,125
-28,027
-17% -$4.1M
FOCL
75
EDAP TMS S.A.
FOCL
$232M
$10.9M 0.26%
1,186,300
+156,300
+15% +$1.6M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Rock Springs Capital Management held 127 positions worth $4.2B, up 0.29% from $4.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management withdrew a net $165M in Q2 2023, closing 4 positions and reducing 16 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $111M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Boston Scientific worth $14.5M.

  • Rock Springs Capital Management's largest Q2 2023 buy was Boston Scientific: 267,500 shares worth $14.5M.
  • Rock Springs Capital Management added most to Humana in Q2 2023, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q2 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $40.3M.
  • Rock Springs Capital Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $111M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $4.2B portfolio in Q2 2023.
  • Rock Springs Capital Management opened 6 new positions and closed 4 in Q2 2023.
  • Rock Springs Capital Management's portfolio value rose 0.29% quarter-over-quarter to $4.2B.

Based on Rock Springs Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.